Prognostic value of plasma MR-proADM vs NT-proBNP for heart failure in people with type 2 diabetes: the SURDIAGENE prospective study

Diabetologia
Mathilde FratySURDIAGENE Study Group

Abstract

N-terminal pro-B-type natriuretic peptide (NT-proBNP) is the gold standard prognostic biomarker for diagnosis and occurrence of heart failure. Here, we compared its prognostic value for the occurrence of congestive heart failure with that of plasma mid-region pro-adrenomedullin (MR-proADM), a surrogate for adrenomedullin, a vasoactive peptide with vasodilator and natriuretic properties, in people with type 2 diabetes. Plasma MR-proADM concentration was measured in baseline samples of a hospital-based cohort of consecutively recruited participants with type 2 diabetes. Our primary endpoint was heart failure requiring hospitalisation. We included 1438 participants (age 65 ± 11 years; 604 women and 834 men). Hospitalisation for heart failure occurred during follow-up (median 64 months) in 206 participants; the incidence rate of heart failure was 2.5 (95% CI 2.2, 2.9) per 100 person-years. Plasma concentrations of MR-proADM and NT-proBNP were significantly associated with heart failure in a Cox multivariable analysis model when adjusted for age, diabetes duration, history of coronary heart disease, proteinuria and baseline eGFR (adjHR [95%CI] 1.83 [1.51, 2.21] and 2.20 [1.86, 2.61], respectively, per 1 SD log10 increment, both p < ...Continue Reading

References

Jun 30, 1994·Biochemical and Biophysical Research Communications·S SugoH Matsuo
Mar 1, 1997·British Journal of Pharmacology·D G Parkes, C N May
Mar 29, 2002·Microscopy Research and Technique·Kazuo KitamuraTanenao Eto
Mar 29, 2002·Microscopy Research and Technique·Naoto MinaminoYoshitaka Isumi
Apr 26, 2002·Journal of Cardiovascular Pharmacology·Noritoshi NagayaKenji Kangawa
Mar 13, 2003·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Toshio NishikimiHiroaki Matsuoka
Aug 16, 2005·Clinical Chemistry·Nils G MorgenthalerAndreas Bergmann
May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
Jul 2, 2009·JAMA : the Journal of the American Medical Association·Olle MelanderThomas J Wang
Mar 21, 2012·European Journal of Heart Failure·John J V McMurrayHenry Krum
Jul 4, 2013·JAMA : the Journal of the American Medical Association·Mark LedwidgeKenneth McDonald
Apr 29, 2014·Diabetes Research and Clinical Practice·Francisco Javier Carrasco-SánchezUNKNOWN RICA investigators
Jan 7, 2015·Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography·Roberto M LangJens-Uwe Voigt
Oct 21, 2015·European Heart Journal. Acute Cardiovascular Care·Philipp BahrmannThomas Bertsch

❮ Previous
Next ❯

Citations

Feb 6, 2021·Journal of Clinical Medicine·Katarzyna CzajkowskaTomasz Hryszko
Apr 26, 2021·Diabetes Research and Clinical Practice·Paul ValensiErwan Donal
Nov 21, 2020·Current Pharmaceutical Design·Catrin SohrabiNikolaos Papageorgiou

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Diabetes

This feed focuses on the latest research on biomarkers used for monitoring disease progression in diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.